390 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
31 Oct 06
Entry into a Material Definitive Agreement
12:00am
Allocation of Purchase Price
ARTICLE 2 DUE DILIGENCE PERIOD
2.1 Due Diligence Period
2.2 Access Agreement
2.3 Preliminary Report
2.4 Supplemental Report …
Exhibit “D”
Assignment of Warranties and General Intangibles
Exhibit “E”
Access Agreement
Exhibit “F”
Deed
Exhibit “G”
Lease
Exhibit “H”
Agreement for Right
424B3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
1 Nov 06
Prospectus supplement
12:00am
of Purchase Price
1.6 Allocation of Purchase Price
ARTICLE 2 DUE DILIGENCE PERIOD
2.1 Due Diligence Period
2.2 Access Agreement
2.3 Preliminary Report
2.4 … ”
Intentionally Deleted
Exhibit “D”
Assignment of Warranties and General Intangibles
Exhibit “E”
Access Agreement
Exhibit “F”
Deed
Exhibit “G”
Lease
Exhibit “H
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Business combination disclosure
5:29pm
platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable … the development of human therapeutic candidates. Over 55 partners currently have access to OmniAb-derived antibodies and more than 250 programs are being
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable … the development of human therapeutic candidates. Over 55 partners currently have access to OmniAb-derived antibodies and more than 250 programs are being
8-K
EX-99.1
bdt99980fcaxvphqt
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K
EX-99
ut7zj 6k97667
3 Mar 04
Financial statements and exhibits
12:00am
8-K
t05tr4ys50w 5h8o
10 May 18
Other Events
6:07am
8-K
EX-99.1
oa1uu0g
24 Dec 08
Ligand Completes Pharmacopeia Acquisition
12:00am
425
EX-99.1
fj0zfa f6dbgmq73sb
21 Jun 22
Business combination disclosure
8:00am
CORRESP
rwv8uxwx
10 Feb 06
Correspondence with SEC
12:00am
8-K
EX-99.1
uk9s8ti28okb
21 Jun 22
Regulation FD Disclosure
6:19am